Ask AI

Novel Targeted Therapies in Hematologic Malignancies

Review expert perspectives on key findings on novel targeted therapies in hematologic malignancies presented at the 2017 ASH annual meeting.

Share

Program Content

Activities

  • Brentuximab Vedotin in CTCL
    Extended Follow-up From the ALCANZA Phase III Trial of Brentuximab Vedotin vs Methotrexate or Bexarotene for Previously Treated CD30-Positive CTCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2017

  • Avapritinib in Advanced Systemic Mastocytosis
    Phase I Study of KIT D816V Inhibitor Avapritinib (BLU-285) in Advanced Systemic Mastocytosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2017

  • Avadomide (CC-122) + Obinutuzumab in R/R NHL
    Phase Ib Study: Avadomide (CC-122) Plus Obinutuzumab in Relapsed/Refractory B-Cell NHL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

  • ACE-CL-003: Acalabrutinib + Obinutuzumab in CLL
    ACE-CL-003: Phase Ib/II Study of Acalabrutinib + Obinutuzumab in Patients With Untreated or R/R CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

  • MAVORIC: Mogamulizumab in CTCL
    Phase III MAVORIC: Mogamulizumab vs Vorinostat in Patients With Previously Treated CTCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2017

  • HERCULES: Caplacizumab in aTTP
    HERCULES: Caplacizumab in Adult Patients With Acquired Thrombotic Thrombocytopenic Purpura
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2017

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology